Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics. https://bit.ly/3UBPDF7
Akari Therapeutics, Plc
Biotechnology Research
Developing novel advanced therapies to address unmet needs of patients with autoimmune & inflammatory diseases.
Über uns
Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).
- Website
-
http://www.akaritx.com
External link for Akari Therapeutics, Plc
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- London
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2015
Standorte
-
Primäre
Wegbeschreibung erhalten
75-76 Wimpole Street
London, W1G 9RT, GB
-
Wegbeschreibung erhalten
1460 Broadway
16th floor
New York, NY 10036, US
Employees at Akari Therapeutics, Plc
-
Samir Patel
Interim President and CEO, Akari Therapeutics Plc
-
Wendy F. DiCicco
Board Member, Financial, Executive & Board Advisor
-
Dr Stuart Ungar
Non Executive Director at Akari Therapeutics PLC, formerly Co-Founder and Board Member at The Doctors Laboratory
-
Wynne Weston- Davies
Medical Director @ Akari Therapeutics | Immunology, Clinical Development
Aktualisierungen
-
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity. https://bit.ly/3Qrz0JE
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
https://www.akaritx.com
-
Join Chief Scientific Officer, Miles Nunn for Akari's poster presentation at the upcoming #ARVO2024 conference on Sunday, May 5th, from 1pm to 2:45pm PT. Find details: https://bit.ly/49ENCMO
-
-
Attending the Association for Research in Vision and Ophthalmology 2024 Annual Meeting? Akari CSO Miles Nunn is presenting new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model on May 5th, at 1pm PT. More information can be found here: https://bit.ly/49ENCMO #ARVO2024
-
-
Akari will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT. Find details: https://bit.ly/49ENCMO #ARVO2024
-
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights. https://bit.ly/43GiRpi
-
On International Women’s Day, Akari celebrates the women of biotech who are making a difference for millions of patients around the world each and every day. #biotech #inspiringinclusion Rachelle Jacques
-
Akari Therapeutics and Peak Bio announce a definitive agreement for a merger of equals in an all-stock transaction. Merger expected to create an expanded pipeline featuring an antibody drug conjugate/ADC toolkit with novel toxin and linker technologies. #biotech https://lnkd.in/e7XbamZT
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
globenewswire.com
-
Join us today in supporting #RareDiseaseDay and the 300 million people worldwide who have rare diseases. Akari is developing advanced therapies for #autoimmune and #inflammatory diseases, including the rare condition #HSCTTMA. https://bit.ly/3uVvbF6 #RareDisease
-
-
This #LowVisionAwarenessMonth learn about pre-clinical PAS-nomacopan as a potential treatment in #GeographicAtrophy (GA) addressing unmet patient needs including longer dose interval and reduction of CNV risk associated with approved GA treatments: https://bit.ly/3Rlji3U